Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2698-2703

  Thomas, Patricia A ^a,b,e   Kirschmann, Dawn A ^a,b   Cerhan, James R ^a,c   Folberg, Robert ^a,b,c   Seftor, Elisabeth A ^a,b   Sellers, Thomas A ^d   Hendrix, Mary J C ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; KERATIN; VIMENTIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS;

AGED; BIOPSY, NEEDLE; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENTS; KERATINS; MIDDLE AGED; PHENOTYPE; POSTMENOPAUSE; SURVIVAL RATE; VIMENTIN;

EID: 0032724043     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Steinert, P. M., and Liem, R. K. Intermediate filament dynamics. Cell, 60: 521-523, 1990.
2. Skalli, O., and Goldman, R. D. Recent insights into the assembly, dynamics, and function of intermediate filament networks. Cell Motil., 19: 67-79, 1991.
3. Chu, Y-W., Runyan, R. B., Oshima, R. G., and Hendrix, M. J. C. Expression of complete keratin filaments in mouse L cells augments cell migration and invasion. Proc. Natl. Acad. Sci. USA, 90: 4261-4265, 1993.
4. Fuchs, E., and Wever, K. Intermediate filaments: structure, dynamics, function, and disease. Annu. Rev. Biochem., 63: 345-382, 1994.
5. Hendrix, M. J. C., Seftor, E. A., Chu, Y-W., Trevor, K. T., and Seftor, R. E. B. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev., 15: 507-525, 1996.
6. Ramaekers, F. C. S., Haag, D., Kant, A., Moesker, O., Hap, P. H. K., and Vooljs, G. P. Coexpression of keratin and vimentin type intermediate filaments in human metastatic carcinoma cells. Proc. Natl. Acad. Sci. USA, 80: 2618-2622, 1983.
7. Sommers, C. L., Walker-Jones, D., Heckford, S. E., Worland, P., Valverius, E., Clark, R., McCormick, F., Stampfer, M., Abularach, S., and Gelmann, E. P. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res., 49: 4258-4263, 1989.
8. Hendrix, M. J. C., Seftor, E. A., Chu, Y-W., Seftor, R. E. B., Nagle, R. B., McDaniel, K. M., Leong, S. P. L., Yohem, K. H., Leibovitz, A., Meyskens, F. L., Conoway, D. H., Welch, D. R., Liotta, L. A., Stetlerand Stevenson, W. G. Coexpression of vimentin and keratin by human melanoma tumor cells: correlation with invasive and metastatic potential. J. Natl. Cancer. Inst., 84: 165-174, 1992.
9. Azumi, N., and Battifora, H. The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. Am. J. Clin. Pathol., 88: 286-296, 1987.
10. Athanassiadou, P., Athanassiades, P., Kyrkou, K., Giahnaki, E., Giannioti, E., and Nanas, S. Expression of vimentin and epidermal growth factor receptor in effusions from patient with breast cancer: correlation with oestrogen and progesterone receptor status. Cytopathology, 4: 91-98, 1993.
11. Ioakim-Liossi, A., Karakitsos, P., Markopoulos, C. H., Aroni, K., Gogas, J., and Kyrkou, K. DNA ploidy and vimentin expression in primary breast cancer. Cytopathology, 6: 325-330, 1995.
12. Hendrix, M. J. C., Seftor, E. A., Seftor, R. E. B., and Trevor, K. T. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am. J. Pathol., 150: 483-495, 1997.
13. Raymond, W. A., and Leong, A. S. Co-expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium. J. Pathol., 157: 299-306, 1989.
14. Santini, D., Ceccarelli, C., Taffurelli, M., Pileri, S., and Marrano, D. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J. Pathol., 179: 386-391, 1996.
15. Bell, C. D., Tischler, E. M., and Laroye, G. J. The relationship of cytoplasmic intermediate filaments and membrane antigens with hormone receptors, nuclear staining density, and mode of stromal invasion in human breast cancer. Breast Cancer Res. Treat., 33: 147-162, 1995.
16. Domagala, W., Markiewski, M., Kubiak, R., Barkowiak, J., and Osborn, M. Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows. Arch. A Pathol. Anat. Histopathol., 423: 497-502, 1993.
17. Domagala, W., Striker, G., Szadowska, A., Dukowicz, A., Harezga, B., and Osborn, M. p53 protein and vimentin in invasive ductal NOS breast carcinoma: relationship with survival and sites of metastases. Eur. J. Cancer, 30A: 1527-1534, 1994.
18. Domagala, W., Lasota, J., Bartowiak, J., Weber, K., and Osborn, M. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am. J. Pathol., 136: 219-227, 1990.
19. Domagala, W., Wozniak, L., Lasota, J., Weber, K., and Osborn, M. Vimentin is preferentially expressed in high-grade ductal and medullary but not in lobular breast carcinomas. Am. J. Pathol., 137: 1059-1064, 1990.
20. Schaller, G., Fuchs, I., Pritze, W., Ebert, A., Hermann, H., Pantel, K., Wetzel, H., and Lengyel, E. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin. Cancer Res., 2: 1879-1885, 1996.
21. Elston, C. W., and Ellis, I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 16: 403-410, 1991.
22. Le Dousal, V., Tubiana-Hulin, M., Friedman, S., Hacene, K., Spyratos, F., and Brunet, M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): an improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer (Phila.), 64: 1914-1921, 1989.
23. Bennett, S. Analysis of survival data by the proportional odds model. Stat. Med., 2: 273-277, 1983.
24. Lippman, M. Growth regulation of breast cancer. Prog. Clin. Biol. Res., 320: 111-119, 1989.
25. Bronzert, D. A., Davidson, N., and Lippman, M. Estrogen and antiestrogen resistance in human breast cancer cell lines. Adv. Exp. Med. Biol., 196: 329-345, 1986.
26. Cowan, K., and Lippman, M. Steroid receptors in breast cancer. Arch. Intern. Med., 142: 363-366, 1982.
27. Thomas, P. A., Raab, S. S., and Cohen, M. B. Is the fine-needle aspiration biopsy diagnosis of proliferative breast disease feasible? Diag. Cytopathol., 11: 301-306, 1994.
28. Thomas, P. A., Cangiarella, J., Raab, S. S., and Waisman, J. Fine needle aspiration biopsy of proliferative breast disease. Mod. Pathol., 8: 130-136, 1995.
29. de Paredes, E. S., Langer, T. G., and Cousins, J. Interventional breast procedures. Curr. Probl. Diag. Radiol., 27: 133-184, 1998.
30. Page, D. L., and Dupont, W. D. Anatomic markers of human premalignancy and risk of breast cancer. Cancer (Phila.), 66: 1326-1335, 1990.
31. Dupont, W. D., Parl, F. R, Hartmann, W. H., Brinton, L. A., Winfield, A. C., Worrell, J. A., Schuyler, P. A., and Plummer, W. D. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer (Phila.), 71: 1258-1265, 1993.
32. Weidner, N., Cady, B., and Goodson, W. H., III. Pathologic prognostic factors for patients with breast carcinoma. Which factors are important? Surg. Oncol. Clin. N. Am., 6: 415-462, 1997.
33. Pinder, S. E., Ellis, I. O., and Elston, C. W. Prognostic factors in primary breast carcinoma. J. Clin. Pathol., 48: 981-983, 1995.
34. Fisher, E. R., Anderson, S., Redmond, C., and Fisher, B. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer (Phila.), 71: 2502-2514, 1993.
35. Moch, H., Scraml, P., Bubendorf, L., Mirlacher, M., Kononen, J., Gasser, T., Mihatsch, M. J., Kallioniemi, O. P., and Sauter, G. High-throughput tissue microarray assay to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol., 154: 981-986, 1999.